Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Bajetta E, et al. Ann Oncol. 2014 Jul;25(7):1373-1378. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12. Ann Oncol. 2014. PMID: 24728035 Free article. Clinical Trial.
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators. Cascinu S, et al. Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735067 Clinical Trial.
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology. Silvani A, et al. Among authors: de simone i. J Neurooncol. 2019 May;142(3):455-462. doi: 10.1007/s11060-019-03116-z. Epub 2019 Feb 6. J Neurooncol. 2019. PMID: 30726533 Clinical Trial.
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernandez ML, Alvisi MF, De Simone I, Rulli E, Nobili A, Casalini G, Antinori S, Gobbi M, Campoli C, Deiana M, Pomari E, Lunardi G, Tessari R, Bisoffi Z. Buonfrate D, et al. Among authors: de simone i. Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6. Int J Antimicrob Agents. 2022. PMID: 34999239 Free PMC article. Clinical Trial.
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
Canova S, Ceresoli GL, Grosso F, Zucali PA, Gelsomino F, Pasello G, Mencoboni M, Rulli E, Galli F, De Simone I, Carlucci L, De Angelis A, Belletti M, Bonomi M, D'Aveni A, Perrino M, Bono F, Cortinovis DL; DIADEM groupD. Canova S, et al. Among authors: de simone i, de angelis a. ESMO Open. 2022 Dec;7(6):100644. doi: 10.1016/j.esmoop.2022.100644. Epub 2022 Dec 1. ESMO Open. 2022. PMID: 36463732 Free PMC article. Clinical Trial.
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C; GARIBALDI Study Group. Reni M, et al. Among authors: de simone i. ESMO Open. 2023 Feb;8(1):100777. doi: 10.1016/j.esmoop.2022.100777. Epub 2023 Feb 1. ESMO Open. 2023. PMID: 36731325 Free PMC article.
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Gori S, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Gori S, et al. Among authors: de simone i. Cancers (Basel). 2023 Oct 4;15(19):4852. doi: 10.3390/cancers15194852. Cancers (Basel). 2023. PMID: 37835546 Free PMC article.
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, Zollo F, Alvisi MF, Perrino M, Cordua N, Borea F, de Vincenzo F, Chella A, Cappelli S, Pardini E, Ballatore Z, Lucarelli A, Ambrosini E, Giuliano M, Pietroluongo E, Mulargiu C, Fabbri A, Prelaj A, Occhipinti M, Brambilla M, Mazzeo L, Beninato T, Vigorito R, Ruggirello M, Greco FG, Calareso G, Miliziano D, Rulli E, De Simone I, Torri V, de Braud FGM, Pasello G, De Placido P, Berardi R, Petrini I, Zucali P, Garassino MC, Lo Russo G. Proto C, et al. Among authors: de simone i. Ann Oncol. 2024 Sep;35(9):817-826. doi: 10.1016/j.annonc.2024.06.002. Epub 2024 Jun 8. Ann Oncol. 2024. PMID: 38857846 Free article. Clinical Trial.
59 results